Cargando…

Structural and temporal dynamics analysis on drug-eluting stents: History, research hotspots and emerging trends

PURPOSE: This review aims to explore the history, research hotspots, and emerging trends of drug-eluting stents(DES)in the last two decades from the perspective of structural and temporal dynamics. METHODS: Publications on DES were retrieved from WoSCC. The bibliometric tools including CiteSpace and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Lili, Wang, Xiangxiu, Yuan, Kungshan, Yin, Tieying, Du, Ruolin, Shen, Li, Zhu, Zhirong, Yu, Suhua, Zhang, Haijun, Wang, Guixue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	KeAi Publishing 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663333/ https://www.ncbi.nlm.nih.gov/pubmed/36406256 http://dx.doi.org/10.1016/j.bioactmat.2022.09.009

Ejemplares similares

Inhibition of in-stent restenosis after graphene oxide double-layer drug coating with good biocompatibility
por: Ge, Shuang, et al.
Publicado: (2019)

The history, hotspots, and trends of electrocardiogram
por: Yang, Xiang-Lin, et al.
Publicado: (2015)

A novel mechanism of inhibiting in-stent restenosis with arsenic trioxide drug-eluting stent: Enhancing contractile phenotype of vascular smooth muscle cells via YAP pathway
por: Zhao, Yinping, et al.
Publicado: (2020)

Cytotoxic effects of docetaxel as a candidate drug of drug-eluting stent on human umbilical vein endothelial cells and the signaling pathway of cell migration inhibition, adhesion delay and shape change
por: Hu, Tingzhang, et al.
Publicado: (2017)

The Janus-faced role of Piezo1 in cardiovascular health under mechanical stimulation
por: Huang, Junyang, et al.
Publicado: (2022)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

The endothelium permeability after bioresorbable scaffolds implantation caused by the heterogeneous expression of tight junction proteins
por: Huang, Junyang, et al.
Publicado: (2022)

A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
por: Ouyang, Hang, et al.
Publicado: (2021)

Randomized clinical trial comparing abluminal biodegradable polymer sirolimus-eluting stents with durable polymer sirolimus-eluting stents: Nine months angiographic and 5-year clinical outcomes
por: Zhang, Haijun, et al.
Publicado: (2016)

Estrogen-Eluting Stents
por: Ryu, Sung Kee, et al.
Publicado: (2009)

Two-year Clinical Outcomes of Patients with Long Segments Drug-Eluting Stents: Comparison of Sirolimus-Eluting Stent with Paclitaxel-Eluting Stent
por: Kim, Ung, et al.
Publicado: (2011)

Everolimus-eluting stents versus sirolimus-eluting stents in patients with cardiac allograft vasculopathy
por: Hawranek, Michał, et al.
Publicado: (2021)

Comparisons of the Effects of Stent Eccentricity on the Neointimal Hyperplasia between Sirolimus-Eluting Stent versus Paclitaxel-Eluting Stent
por: Kim, Byeong-Keuk, et al.
Publicado: (2010)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents
por: Faramarzi, Negar, et al.
Publicado: (2013)

Everolimus-eluting coronary stents
por: Saez, Alejandro, et al.
Publicado: (2010)

Antibiotic eluting sinus stents
por: Thompson, Harrison M., et al.
Publicado: (2020)

Phagocytosis of polymeric nanoparticles aided activation of macrophages to increase atherosclerotic plaques in ApoE(−/−) mice
por: Yin, Tieying, et al.
Publicado: (2021)

Biodegradable polymeric nanoparticles increase risk of cardiovascular diseases by inducing endothelium dysfunction and inflammation
por: Shi, Wen, et al.
Publicado: (2023)

Correction: Biodegradable polymeric nanoparticles increase risk of cardiovascular diseases by inducing endothelium dysfunction and inflammation
por: Shi, Wen, et al.
Publicado: (2023)

Ureteral stent technology: Drug-eluting stents and stent coatings
por: Yang, Luo, et al.
Publicado: (2015)

Biodegradable polymer everolimus-eluting stents versus contemporary drug-eluting stents: a systematic review and meta‑analysis
por: Yin, Juntao, et al.
Publicado: (2023)

Stent Fracture after Everolimus-Eluting Stent Implantation
por: Almasood, Ali S., et al.
Publicado: (2011)

Early definite stent thrombosis with everolimus-eluting stents
por: Naito, Ryo, et al.
Publicado: (2015)

Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
por: Ohri, Nisha, et al.
Publicado: (2015)

Two-stage degradation and novel functional endothelium characteristics of a 3-D printed bioresorbable scaffold
por: Yin, Tieying, et al.
Publicado: (2021)

A novel PDGF receptor inhibitor-eluting stent attenuates in-stent neointima formation in a rabbit carotid model
por: Huang, Chen, et al.
Publicado: (2017)

Drug eluting stents: Focus on Cypher™ sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions
por: Chieffo, Alaide, et al.
Publicado: (2007)

Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
por: Velders, Matthijs A., et al.
Publicado: (2013)

Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?
por: Gherasie, Flavius-Alexandru, et al.
Publicado: (2023)

Clinical results of everolimus-eluting stents and sirolimus-eluting stents in patients undergoing percutaneous coronary intervention
por: Jafaripour, Iraj, et al.
Publicado: (2023)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Influence of valsartan-eluting stent on neointima formation
por: Guihua, Li, et al.
Publicado: (2010)

Everolimus-eluting stents in interventional cardiology
por: Townsend, Jacob C, et al.
Publicado: (2012)

Drug-eluting metallic stents in urology
por: Kallidonis, Panagiotis S., et al.
Publicado: (2014)

Value of M2BP in predicting in‐stent restenosis in patients after coronary drug‐eluting stent implantation
por: Yang, Le, et al.
Publicado: (2022)

Incidence and natural history of coronary evagination after implanted biodegradable polymer sirolimus-eluting stent
por: Tsuji, Keiko, et al.
Publicado: (2022)

Distinctive effects of CD34- and CD133-specific antibody-coated stents on re-endothelialization and in-stent restenosis at the early phase of vascular injury
por: Wu, Xue, et al.
Publicado: (2015)

Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions
por: Kassaian, SE, et al.
Publicado: (2010)

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V(®))
por: Sheiban, Imad, et al.
Publicado: (2008)

Correction: Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
por: Velders, Matthijs A., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tgpe3rf2o1doosh22j652q4i4r